STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2151 by analyst upside · 2026-06-27
ACAD
ACADIA Pharmaceuticals Inc.
Healthcare · Market Cap $4B · P/E 11.5x
ANALYST PRICE TARGET
+25.0%
implied upside to consensus target
Current Price $25.32
Consensus Target $31.65
Bull Target $45.0
Bear Target $17.0
Analysts Covering 20
ANALYST CONSENSUS — BUY
Strong Buy
4
Buy
11
Hold
4
Sell
1
52-Week Low $19.69
52-Week High $28.35
YTD Return -3.7%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) 11.5x
Forward P/E 29.2x
EPS (TTM) $2.21
PEG Ratio 50.86
Dividend Yield N/A
Revenue (TTM) $1.1B
Profit Margin 34.3%
52-WEEK RANGE
52-Week Low $19.69
52-Week High $28.35
Current Price $25.32
Bear Target $17.0
Bull Target $45.0
● Now $25.32 ● Target $31.65
TRADING DATA
Avg Volume 1.6M
YTD Return -3.7%
Analyst Count 20
Consensus Buy
Upside to Target +25.0%
Last Updated 2026-06-27

ANALYST SUMMARY

ACADIA Pharmaceuticals Inc. (ACAD) is currently trading at $25.32 with a Wall Street consensus price target of $31.65, implying potential upside of 25.0% over the next 12 months. 20 analysts currently cover ACAD, with a consensus rating of Buy — 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $45.0, while the most cautious has a target of $17.0.

ACAD operates in the Healthcare sector with a market capitalisation of $4B. The stock is down 3.7% year-to-date and is currently trading near the upper end of its 52-week range of $19.69 – $28.35.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ACAD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citigroup — Reiterated
Buy → Buy 2026-05-08 Building track record
B of A Securities ↑ Upgrade
Neutral → Buy 2026-03-25 Building track record
JP Morgan — Reiterated
Overweight → Overweight 2026-03-04 43% win rate (7 calls)
TD Cowen — Reiterated
Buy → Buy 2026-02-26 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-02-26 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2026-02-26 Building track record
Stifel — Reiterated
Hold → Hold 2026-02-26 Building track record
Wolfe Research ● Initiated
Outperform 2026-02-24 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →